Aura Biosciences Stock

aurabiosciences.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $225.08MM

Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Register for Details

For more details on financing and valuation for Aura Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Aura Biosciences.

Register Today

Team

Management Team

Elisabet de los Pinos Ph.D
Co-Founder, Chief Executive Officer & Board Member
Denis O'Shaughnessy Ph.D
Head of Clinical Development
Richard Peters Ph.D
Advisor
Andrew Russell Ph.D
Director, Manufacturing
Stephen Monks Ph.D
Senior Vice President, Development
Alan Walts Ph.D
Executive Chairman
Julie Feder
Chief Financial Officer
Cadmus Rich MD
Chief Medical Officer
Michele Keough
Senior Vice President, R&D Operations

Board Members

Dale Pfost Ph.D
Advent Venture Partners
Elisabet de los Pinos Ph.D
Casper Breum
Lundbeckfonden
Henri Termeer
Javier García
Columbus Venture Partners
Rajesh Parekh Ph.D
Advent Life Sciences
Arthur Pappas
Chiesi Ventures
Giovanni Mariggi Ph.D
Medicxi
Joël Jean-Mairet Ph.D
Ysios Capital
Salvador Garcia-Atance Ph.D
Israel Ruiz
Alan Walts Ph.D
Mark Chin
Arix Bioscience

Other companies like Aura Biosciences in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors
Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tum
Updated on: Sep 25, 2023